Acme Resources is a non-banking financial company that provides credit and financing services while also engaging in the purchase and sale of real estate properties.
The company lacks a sustainable competitive advantage, as evidenced by negative net margins and an average ROCE of only 3.5%, which is well below the cost of capital. There is no evidence of brand power or cost advantages, and the business is highly dependent on cyclical real estate sales to supplement weak lending income.
Management has failed to generate value, with revenue and EPS declining at high single and double-digit rates respectively over the period. Capital is largely tied up in non-performing assets and real estate inventory that has faced regulatory attachment, resulting in poor returns on equity.
The company's collapse was precipitated by the conversion of massive contingent tax liabilities into actual cash outflows, which the business could not service given its negative margins and shrinking revenue base. As the Income Tax Department finalized the attachment of core inventory, the firm lost its primary source of supplemental income, leading to a liquidity crunch. The exodus of key leadership in 2025 left a rudderless ship to navigate complex litigation, eventually resulting in a fire sale of non-performing assets at steep discounts to book value.
RichFakir rates Acme Resources Ltd's business quality as poor — 15/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Acme Resources Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Acme Resources Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Acme Resources Ltd's fair value is about ₹9 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →